Navigation Links
FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
Date:9/19/2012

WATERTOWN, Mass., Sept. 19, 2012 /PRNewswire/ -- Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that Enanta was named by FierceBiotech as one of 2012's Fierce 15.

The annual award, which was announced today during the BioPharm America Conference at the Westin Boston Waterfront Hotel in Boston, was created by FierceBiotech to recognize 15 promising private biotech companies selected from around the world for their potential to have impact on the treatment of human diseases. This is FierceBiotech's tenth annual Fierce 15 selection. Every year, FierceBiotech evaluates hundreds of private companies for the list, which is based on a variety of factors including the strength of each company's technology, partnerships, venture funding and a competitive market position.

"While biotechs have been scrambling in the race to the market with an interferon-free treatment for hepatitis C, Enanta has been building its pipeline of compounds for use in HCV combination therapies," said FierceBiotech Editor John Carroll. "It's struck key partnerships with Abbott and Novartis and has additional unpartnered programs."

"We are honored to be chosen as one of the Fierce 15 and recognized for our work in the infectious disease field—specifically, our work in multiple HCV drug classes designed for use against the hepatitis C virus," commented Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta. "Our goal of providing patients with innovative therapies that are safer and more effective than current treatments is what motivates our employees every day."

About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create best in class small molecule drugs in the infectious disease field. Enanta is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with Abbott), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, the company has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a current focus on developing intravenous and oral treatments for hospital and community MRSA infections. Enanta is a privately-held company headquartered in Watertown, Massachusetts. Enanta's news releases and other information are available on the company's website at www.enanta.com.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 100,000 top biotech and pharma professionals rely on FierceBiotech for an insider briefing on the day's top stories. Sign up is free at www.fiercebiotech.com.

Investor Contact
Carol Miceli
Enanta Pharmaceuticals, Inc.
617-607-0710
cmiceli@enanta.com

Media Contact
Kari Watson
MacDougall Biomedical Communications
781-235-3060
kwatson@macbiocom.com


'/>"/>
SOURCE Enanta Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
2. Islet Sciences Names Richard A. Franco, Sr. to its Board of Directors
3. Elsevier / MEDai Names Dr. Peter Edelstein as Chief Medical Officer and Dr. Gerald Osband as Director of Product Strategy
4. PharmaVOICE Names Four inVentiv Health Associates Among "100 Most Inspiring" Leaders in Healthcare
5. Lloyd Library and Museum Names ABCs Blumenthal to New Honorary Advisory Board
6. Ethical Corporation Names Life Technologies First CSO Sustainability Executive of the Year
7. Triple-S Management Corporation Announces the Retirement of Socorro Rivas-Rodriguez; Names Pablo Almodovar Scalley as Successor
8. 23andMe Names Andy Page to Board of Directors
9. Biggest Names in Pharmaceutical, Healthcare Industry to Gather for Groundbreaking Event in Parsippany, New Jersey on September 11-12, 2012
10. BioMotiv Launches Novel Drug Development Operation, Names Leadership Team
11. Sapphire Energy Names New Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... CAMBRIDGE, Mass. and ... 2016 SystemOne, a company focused on ... for the developing world, and Daktari Diagnostics, a ... with its portable and ultrasensitive immunoassay-based CarePlatform™, today ... and license agreement to integrate Daktari,s technology platform ...
(Date:12/2/2016)... 2, 2016 CytRx Corporation (NASDAQ: ... in oncology, today announced the appointment of Earl ... consultant, and private healthcare investor, to its Board of ... with clinical and strategic experience at the highest level," ... CEO. "As one of the world,s leading orthopedic surgeons, ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... (CSS) and the popularity of US Single Day Events (SDE) to organize a ... Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and life sciences industry ...
(Date:12/2/2016)... ... December 02, 2016 , ... Robots will storm the Prudential Center in Boston, ... The event, which is held on the United Nations International Day of Persons with ... into the workplace. Suitable Technologies is partnering with NTI to showcase how technology can ...
Breaking Biology Technology:
(Date:11/19/2016)... Securus Technologies, a leading provider of civil and criminal ... monitoring, announced today that it has offered a challenge ... technology judge determine who has the largest and best ... platform, and the best customer service. "ICSolutions ... we do – which clearly is not the case ...
(Date:11/17/2016)... that it has just released a new white paper authored by Zettar that covers ... data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a complicated ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
Breaking Biology News(10 mins):